Any current/future new fundraising through debt or equity?

The company has applied for in-principle approval from the exchange to raise funds through a new fundraising round. The proposed fundraise aims to support growth opportunities, including capital expenditure and operational funding. This fundraise is distinct from the last rights issue conducted six months ago, which was primarily for additional capacity build-up. The promoter has limited resources, so equity fundraising supplements debt capacity. Debt remains the company's preferred financing option, but access is constrained for SMEs due to collateral and cost challenges. As the company grows

Any current/future capex/capital investment/strategic investment?

The company is undertaking a Greenfield project on plot C3, expected to be operational by end of FY27, adding 400 to 500 metric tons capacity. An adjoining plot was purchased in February to expand QC and R&D facilities and build a food-grade emulsifier facility with required certification; expected online by end FY27 or early FY28. The new food-grade facility will add 200 to 250 metric tons of capacity, though exact numbers may vary due to certification. Space provisions exist on the new plot to potentially add another 300 to 500 metric tons capacity in the future. The rights issue in November

Future growth expectations in sales/revenue/volumes?

FY26 revenue growth was lower than previously guided (60% vs expected 100%) due to unforeseen global issues and February-March market panic. Australia market shipment recently started; targeted revenue of ₹75 crore cumulatively over FY26-FY28 expected. New American subsidiary set up; contribution to revenue expected from FY27 onwards, targeting oil, gas, and other industries. Current capacity supports approx. ₹230-260 crore revenue; new Greenfield facility (400-500 MT capacity) expected operational by end FY27, boosting capacity. Additional adjoining land acquired for QC, R&D, and food-grade e

Future growth expectations in earnings/operating earnings/profits/EPS?

FY26 saw strong growth: Revenue +57%, EBITDA +24.22%, PAT +21.83%. Margins moderated due to prioritizing volume growth and geographic expansion. Expect gradual margin improvement driven by scale efficiencies and better procurement. Increased working capital deployment reflects expansion; cash conversion cycle remains stable. New Greenfield facility to be operational by end FY27, substantially expanding capacity. International markets (Australia, USA) expected to contribute growing revenue. Procurement improvements and macroeconomic stabilization anticipated to support better bottom-line. Right

Current/ Expected Orderbook/ Pending Orders?

The transcript does not explicitly mention the current or expected order book or pending orders in specific numerical terms. However, there are references to new business uptake and sales expectations: - Australia: Expect uptake this year and next with targets of about ₹75 crore cumulative revenue over three years. - American subsidiary: Started contributing revenue already with expected scaling up in FY27 onwards. Capacity expansion is underway to meet growing demand, indicating an anticipation of increased orders. The company is focused on scaling capacity, deepening footprint, and opera

IN US

Indian EmulsQ1 FY27Chemicals & Petrochemicals

Indian Emuls Q1 FY27 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹42P/E: 4.6Market Cap: ₹74 CrSector: Chemicals & Petrochemicals

Management growth scorecard

Revenue

Category 2

Margin

Category 2

Fundraise

Yes

Order

N/A

Capex

Yes

2 of 4 growth signals are positive.

Full analysis

Revenue guidance

Category 2

→FY26 revenue growth was lower than previously guided (60% vs expected 100%) due to unforeseen global issues and February-March market panic.
→Australia market shipment recently started; targeted revenue of ₹75 crore cumulatively over FY26-FY28 expected.
→New American subsidiary set up; contribution to revenue expected from FY27 onwards, targeting oil, gas, and other industries.
→Current capacity supports approx. ₹230-260 crore revenue; new Greenfield facility (400-500 MT capacity) expected operational by end FY27, boosting capacity.
→Additional adjoining land acquired for QC, R&D, and food-grade emulsifier products with certifications; expected addition by early FY28.
→The company anticipates scaling volumes aggressively with gradual margin improvements as procurement and macroeconomic conditions stabilize.
→Management confident in long-term growth by expanding capacity, deepening market footprint, and product diversification aligned with upcoming facilities and certifications.

Margin guidance

Category 2

→FY26 saw strong growth: Revenue +57%, EBITDA +24.22%, PAT +21.83%.
→Margins moderated due to prioritizing volume growth and geographic expansion.
→Expect gradual margin improvement driven by scale efficiencies and better procurement.
→Increased working capital deployment reflects expansion; cash conversion cycle remains stable.
→New Greenfield facility to be operational by end FY27, substantially expanding capacity.
→International markets (Australia, USA) expected to contribute growing revenue.
→Procurement improvements and macroeconomic stabilization anticipated to support better bottom-line.
→Rights issue timing and pricing will be decided considering market conditions; focus on long-term value.
→EBITDA margin guidance remains in a broad range (historically around 19-20%), with some fluctuations expected during growth phase.
→Volume-driven margin changes projected to stabilize with volume gains and product mix improvements.
→Long-term strategy focuses on scaling capacity, operational efficiency, and sustained earnings growth over 3-5 years.

3 more insights locked — sign up free to unlock

Fundraise plans

Yes

→The company has applied for in-principle approval from the exchange to raise funds through a new fundraising round.
→The proposed fundraise aims to support growth opportunities, including capital expenditure and operational funding.
→This fundraise is distinct from the last rights issue conducted six months ago, which was primarily for additional capacity build-up.
→The promoter has limited resources, so equity fundraising supplements debt capacity.
→Debt remains the company's preferred financing option, but access is constrained for SMEs due to collateral and cost challenges.
→As the company grows, it expects improved access and terms for debt financing.
→Any future fundraising details will only be finalized after exchange approval and will be communicated through official channels.

Order book

→The transcript does not explicitly mention the current or expected order book or pending orders in specific numerical terms.
→However, there are references to new business uptake and sales expectations:
→ - Australia: Expect uptake this year and next with targets of about ₹75 crore cumulative revenue over three years.
→ - American subsidiary: Started contributing revenue already with expected scaling up in FY27 onwards.
→Capacity expansion is underway to meet growing demand, indicating an anticipation of increased orders.
→The company is focused on scaling capacity, deepening footprint, and operational efficiency for growth.
→No detailed quantitative order book or backlog figures were disclosed in the provided transcript.

Capex plans

Yes

→The company is undertaking a Greenfield project on plot C3, expected to be operational by end of FY27, adding 400 to 500 metric tons capacity.
→An adjoining plot was purchased in February to expand QC and R&D facilities and build a food-grade emulsifier facility with required certification; expected online by end FY27 or early FY28.
→The new food-grade facility will add 200 to 250 metric tons of capacity, though exact numbers may vary due to certification.
→Space provisions exist on the new plot to potentially add another 300 to 500 metric tons capacity in the future.
→The rights issue in November funded the upcoming capacity addition and capital expenditure.
→Additional debt has been taken to support expansion of QC, R&D, and new food-grade facility.
→A proposed future fundraise is under application with the exchange for multiple objects, including investment in sister companies and further growth capital.

How does Indian Emuls rank vs peers in Chemicals & Petrochemicals?

Pro feature

1Indian Emuls

Rev 2Mar 2

See full Chemicals & Petrochemicals sector rankings

Want more stocks like Indian Emuls?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio